Pharmaceutical composition for preventing and treating central nervous system diseases containing fluoxetine and vitamin c as active ingredients

Abstract

The present invention relates to a pharmaceutical composition for the prevention and treatment of blood-brain barrier disorder and central nervous system diseases containing fluoxetine and vitamin C as active ingredients. Specifically, when low concentration of fluoxetine and vitamin C, which did not show any improved effect on the blood-brain barrier disorder and disruption of blood-spinal cord barrier when administered alone, were mixed and co-administered to an animal model with spinal cord injury and transient global ischemia, the co-administration significantly increased the effect of inhibiting the increase of permeability of blood-spinal cord barrier and the effect of inhibiting MMP-9 activation and the effect of alleviating the influx of blood cells in an animal model with spinal cord injury; and the effect of inhibiting the disruption of blood-brain barrier and the effect of recovering memory in a transient global ischemia animal model, compared to the single administration of fluoxetine or vitamin C at the same concentration. The results indicate the synergy effect and the decrease of side effects by the co-administration of the compound at a low concentration, and thus fluoxetine and vitamin C of the present invention can be effectively used as active ingredients for a pharmaceutical composition for the prevention and treatment blood-brain barrier disorder and central nervous system diseases.

1 . A method for treating a cerebral ischemic injury comprising the step of administering fluoxetine and vitamin C to a subject having the cerebral ischemic injury, wherein the fluoxetine and vitamin C are administered in a ratio of from 1:500 to 1:10; wherein the fluoxetine is administered in an amount of from 0.8 mg/kg to 2 mg/kg to the subject; and wherein the vitamin C is administered in an amount of from 70 mg/kg to 150 mg/kg to the subject. 
     
     
         2 . The method of  claim 1 , wherein the fluoxetine and vitamin C are co-administered to the subject. 
     
     
         3 . The method of  claim 2 , wherein the fluoxetine and vitamin C are co-administered to the subject in a composition comprising the fluoxetine and vitamin C. 
     
     
         4 . The method of  claim 1 , wherein the method consists essentially of administering fluoxetine and vitamin C to the subject.